Effect of indomethacin-coated posterior chamber intraocular lenses on postoperative inflammation and posterior capsule opacification.
We implanted indomethacin-coated intraocular lenses (IOLs) in rabbit eyes to ascertain how the sustained release of the drug affects postoperative inflammation and posterior capsule opacification (PCO). A preoperative resolution test showed that 1% indomethacin-coated IOLs placed in balanced salt solution released a mean 14.0 +/- 0.6 micrograms of the drug within 24 hours. Postoperatively, aqueous flare intensity in eyes with 0.1% indomethacin-coated IOLs and in eyes with 1.0% indomethacin-coated IOLs was significantly less at day 2 and at days 2 and 3, respectively, than in control eyes with uncoated lenses. In another group of eyes, histopathological examination showed that those with 1.0% indomethacin-coated lenses had significantly less PCO than the contralateral control eyes with uncoated IOLs.
D000818:Animals; D001672:Biocompatible Materials; D018916:Blood-Aqueous Barrier / Q000502:physiology; D003692:Delayed-Action Preparations; D004848:Epithelium / Q000473:pathology; D007213:Indomethacin / Q000008:administration & dosage*; D007249:Inflammation / Q000517:prevention & control; D007903:Lens Capsule, Crystalline / Q000187:drug effects / Q000473:pathology*; D007908:Lens, Crystalline / Q000473:pathology; D007910:Lenses, Intraocular; D011183:Postoperative Complications / Q000517:prevention & control; D011817:Rabbits
D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D007213:Indomethacin